NewLimit wants to end aging.
What’s happening: The biotech company co-founded by Coinbase CEO Brian Armstrong raised a $130M Series B led by Kleiner Perkins, with backing from Khosla Ventures, Founders Fund, Human Capital, Valor Equity, and others.
Ageless. NewLimit develops therapies using epigenetic reprogramming, restoring human cells to a younger, healthier state. Thinking big, it aims to extend healthspan and delay age-related diseases.
Fast track. NewLimit combines scaled biological experiments with AI and single-cell sequencing to rapidly screen thousands of therapies. A full-stack approach, it reduces costs, increases speed, and prioritizes only the most promising drug candidates.
Citing its progress in restoring liver and immune cells, new funding will support research of additional cell types to unlock a platform of age-defying medicines.
Moonshot. Calling aging “the meta driver of nearly every major human disease,” Armstrong believes reversing cellular decline could be the biggest opportunity in biotech. Kleiner’s Ilya Fushman agrees, calling it one of the most consequential scientific efforts of our time.
Looking ahead: Non-human primate trials could begin as early as 2026, with human trials on the horizon by 2028. Ambitious yet promising, as Armstrong puts it, “We doubled life expectancy once. Why can’t we double it again?”
